Clinical Trial Update: Reversing Therapy Resistance With Epigenetic-Immune Modification [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating epigenetic-immune modification to reverse therapy resistance in breast neoplasms has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Snippet

Sponsor: University of California, San Francisco | Conditions: Breast Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2020-07-07